Barinka Cyril, Rovenská Miroslava, Mlcochová Petra, Hlouchová Klára, Plechanovová Anna, Majer Pavel, Tsukamoto Takashi, Slusher Barbara S, Konvalinka Jan, Lubkowski Jacek
Center for Cancer Research, National Cancer Institute at Frederick, Frederick, Maryland 21702, USA.
J Med Chem. 2007 Jul 12;50(14):3267-73. doi: 10.1021/jm070133w. Epub 2007 Jun 14.
Inhibition of glutamate carboxypeptidase II (GCPII) has been shown to be neuroprotective in multiple preclinical models in which dysregulated glutamatergic transmission is implicated. Herein, we report crystal structures of the human GCPII complexed with three glutamate mimetics/derivatives, 2-(phosphonomethyl)pentanedioic acid (2-PMPA), quisqualic acid (QA), and L-serine O-sulfate (L-SOS), at 1.72, 1.62, and 2.10 A resolution, respectively. Despite the structural differences between the distal parts of the inhibitors, all three compounds share similar binding modes in the pharmacophore (i.e., S1') pocket of GCPII, where they are stabilized by a combination of polar and van der Waals interactions. The structural diversity of the distal parts of the inhibitors leads to rearrangements of the S1' site that are necessary for efficient interactions between the enzyme and an inhibitor. The set of structures presented here, in conjunction with the available biochemical data, illustrates a flexibility of the GCPII pharmacophore pocket and highlights the structural features required for potent GCPII inhibition. These findings could facilitate the rational structure-based drug design of new GCPII inhibitors in the future.
在多种涉及谷氨酸能传递失调的临床前模型中,抑制谷氨酸羧肽酶II(GCPII)已显示出神经保护作用。在此,我们报告了人GCPII与三种谷氨酸模拟物/衍生物2-(膦酰甲基)戊二酸(2-PMPA)、喹啉酸(QA)和L-丝氨酸O-硫酸盐(L-SOS)复合的晶体结构,分辨率分别为1.72、1.62和2.10埃。尽管抑制剂远端部分存在结构差异,但所有三种化合物在GCPII的药效团(即S1'口袋)中具有相似的结合模式,它们通过极性相互作用和范德华相互作用的组合得以稳定。抑制剂远端部分的结构多样性导致S1'位点重排,这对于酶与抑制剂之间的有效相互作用是必要的。本文展示的这组结构,结合现有的生化数据,阐明了GCPII药效团口袋的灵活性,并突出了强效抑制GCPII所需的结构特征。这些发现可能有助于未来基于合理结构的新型GCPII抑制剂药物设计。